Swiss-based SHL Medical, a global developer and manufacturer of self-injection solutions has opened a $220m manufacturing facility in North Charleston, South Carolina, as part of its strategy to expand global production of autoinjectors.
This 33445sqm site, which has already created over 300 jobs, will help the company meet the increasing global demand for autoinjectors, particularly in the cardiometabolic sector. It includes medical device injection moulding technology and automated assembly capabilities.
The facility will manufacture the autoinjectors used in medications in various therapeutic areas, including endocrine and metabolic disorders, musculoskeletal diseases, and dermatology.
According to Ulrich Faessler, CEO and chairman of SHL Medical, “US-based production is a major step forward in our global expansion and reinforces our position as the leader in providing end-to-end drug delivery solutions.”
“With our established site in Taiwan and the upcoming facility in Switzerland, we will be the only autoinjector manufacturer operating across three continents, bringing us even closer to our customers,” he added.
Kimberlee Steele, SHL Medical’s North America managing director, said “The most trusted autoinjector brand is now made in the USA. We are proud to be contributing to the growth of the local economy and becoming a key player in the area while contributing to our sustainability goals.”
The U.S. expansion also supports SHL’s goal of producing 1.5 billion devices by 2025, bolstered by recent acquisitions under its SHL Advantec division.
